

7841-89

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)

097402446

INTERNATIONAL APPLICATION NO.
PCT/CA98/00325INTERNATIONAL FILING DATE
7 April 1998PRIORITY DATE CLAIMED
7 April 1997

TITLE OF INVENTION

INTRAVENOUS IMMUNE GLOBULIN FORMULATION CONTAINING A NON-IONIC SURFACE
ACTIVE AGENT WITH IMPROVED PHARMACOKINETIC PROPERTIES

APPLICANT(S) FOR DO/EO/US

Hugh W. Price and B. Michael R. Woloski

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - (a) ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - (b) ☒ has been transmitted by the International Bureau.
 - (c) ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - (a) ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - (b) ☐ have been transmitted by the International Bureau.
 - (c) ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - (d) ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A **SUBSTITUTE SPECIFICATION**.
15. ☐ A **CHANGE OF POWER OF ATTORNEY AND/OR ADDRESS LETTER**.
16. ☐ Other items or information:

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <div style="font-size: 24pt; font-weight: bold; margin-top: 5px;">09/4 02446</div>		INTERNATIONAL APPLICATION NO. PCT/CA98/00325		ATTORNEY'S DOCKET NUMBER 7841-89	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by EPO or JPO \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$840.00 Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)). \$				CALCULATIONS PTO USE ONLY	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	- 20 =		x \$18.00	\$	
Independent Claims	- 3 =		x \$78.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) No			+ \$260.00	\$0	
TOTAL OF ABOVE CALCULATIONS =				\$	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +				\$	
TOTAL NATIONAL FEE =				\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$840.00	
				Amount to be refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> a check in the amount of \$ \$840.00 to cover the above fees is enclosed. (Cheque No. _____)					
b. <input type="checkbox"/> Please charge my Deposit Account No. 02-2095 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2095. A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Micheline Gravelle Bereskin & Parr Box 401, 40 King Street West Toronto, Ontario, Canada M5H 3Y2				<div style="text-align: center;"> Signature <u>Micheline Gravelle</u> Name <u>40,261</u> Registration No.</div>	

BERESKIN & PARR
Box 401
40 King Street West
Toronto, Canada
M5H 3Y2

Telephone (416) 364-7311
Telecopier (416) 361-1398
Internet BERESKIN&PARR.COM
Cable ARNBEE Toronto

October 6, 1999

The Commissioner of Patents & Trademarks
Washington, D.C., U.S.A. 20231

Dear Sir:

Transmitted herewith for entry into national phase of the patent application of

Inventors: Hugh W. Price and B. Michael R. Woloski


For: **INTRAVENOUS IMMUNE GLOBULIN FORMULATION CONTAINING A
NON-IONIC SURFACE ACTIVE AGENT WITH IMPROVED
PHARMACOKINETIC PROPERTIES**

The following papers are enclosed:

The following papers are enclosed:

- [X] Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) concerning a filing under 35 U.S.C. 371.
- [X] Preliminary Amendment.
- [X] An unsigned Combined Declaration for Patent Application and Power of Attorney.
- [X] The government filing fee in the amount of \$840.00 is included in our cheque No. _____. Please charge any deficiency or credit any overpayment to our deposit account No. 02-2095. A duplicate copy of this sheet is enclosed.
- [X] PAYMENT OF THE CLAIM FEES IS BEING DEFERRED.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 02-2095.
- [X] Convention priority is requested based on United States Provisional Application No. 60/041,921 filed on 7 April 1997.

Respectfully submitted,



Micheline Gravelle
Registration No. 40,261